Phathom Pharmaceuticals, Inc. Non-current Revenue (Deferred)

Non-current Revenue (Deferred) of PHAT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Non-current Revenue (Deferred) growth rates and interactive chart.


Highlights and Quick Summary

  • Non-current Revenue (Deferred) for the quarter ending June 29, 2019 was $0 (a NaN% decrease compared to previous quarter)
Visit stockrow.com/PHAT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Non-current Revenue (Deferred) of Phathom Pharmaceuticals, Inc.

Most recent Non-current Revenue (Deferred)of PHAT including historical data for past 10 years.

Interactive Chart of Non-current Revenue (Deferred) of Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc. Non-current Revenue (Deferred) for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2019 $0.0 $0.0
2018 $0.0

Business Profile of Phathom Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.